Abstract: The present invention includes methods of treating obsessive-compulsive disorder and/or an obsessive-compulsive related disorder or disease. The present invention further includes methods of treating symptoms of a compulsive-like behavior, obsessive-compulsive related disorder, and/or compulsive-like behaviors in an autism spectrum disorder or disease. In certain embodiments, the method comprises administering to the subject a therapeutically effective amount of a positive allosteric ?4?2 nicotinic acetylcholine receptor modulator, alone or in combination with another positive allosteric ?4?2 nicotinic acetylcholine receptor modulator or an additional agent known to treat the symptoms of obsessive-compulsive disorder, an obsessive-compulsive related disorder, and/or compulsive-like behaviors in autism spectrum disorder or disease.

Abstract: ?-hydroxyphenylalkylamines and their use for lowering and controlling ocular hypertension and treating glaucoma are disclosed.

Abstract: Spiro[9,10-dihydroanthracene]-9,3′-pyrrolidine (SPAN) and derivatives thereof are provided as selective serotonin receptor antagonists. The compounds are selective, high affinity antagonists of 5-HT2 serotonin receptors. The compounds are useful as antidepressant and antianxiety agents.

Abstract: Spiro[9,10-dihydroanthracene]-9,3′-pyrrolidine (SPAN) and derivatives thereof are provided as selective serotonin receptor antagonists. The compounds are selective, high affinity antagonists of 5-HT2 serotonin receptors. The compounds are useful as antidepressant and antianxiety agents.

Abstract: Compounds which have enhanced affinity and selectivity for 5-HT6 receptors have been identified. These compounds can be used therapeutically in the treatment of mental disorders via administration in a pharmacologically acceptable delivery route to a patient in need thereof, or can be used to identify antagonists of 5-HT6 receptors by well known screening methodologies which could themselves be used in the treatment of mental disorders.

Abstract: Compounds which have enhanced affinity and selectivity for 5-HT6 receptors have been identified. These compounds can be used therapeutically in the treatment of mental disorders via administration in a pharmacologically acceptable delivery route to a patient in need thereof, or can be used to identify antagonists of 5-HT6 receptors by well known screening methodologies which could themselves be used in the treatment of mental disorders.

Abstract: Compounds which have enhanced affinity and selectivity for 5-HT6 receptors have been identified. These compounds can be used therapeutically in the treatment of mental disorders via administration in a pharmacologically acceptable delivery route to a patient in need thereof, or can be used to identify antagonists of 5-HT6 receptors by well known screening methodologies which could themselves be used in the treatment of mental disorders.

Abstract: Compounds which have enhanced affinity and selectivity for 5-HT6 receptors have been identified. These compounds can be used therapeutically in the treatment of mental disorders via administration in a pharmacologically acceptable delivery route to a patient in need thereof, or can be used to identify antagonists of 5-HT6 receptors by well known screening methodologies which could themselves be used in the treatment of mental disorders.

Abstract: Compounds which have enhanced affinity and selectivity for 5-HT6 receptors have been identified. These compounds can be used therapeutically in the treatment of mental disorders via administration in a pharmacologically acceptable delivery route to a patient in need thereof, or can be used to identify antagonists of 5-HT6 receptors by well known screening methodologies which could themselves be used in the treatment of mental disorders.

Abstract: This invention relates compounds having serotonin receptor binding activity, to pharmaceutical compositions containing them and to their medical use, particularly in the treatment of CNS conditions. Described herein are compounds which have the general formula: wherein R1 is selected from H, C1-6alkyl and benzyl; R2 is selected from H and C1-6alkyl; R3 is selected from H and C1-6alkyl; R4 is selected from C1-6alkyl and halo; R5 is selected from H and OH; and salts, hydrates and solvates thereof. Also described is the use of these compounds as pharmaceuticals to treat indications where stimulation of subtypes of the serotonin receptor is implicated, such as migraine.

Abstract: This invention relates compounds having serotonin receptor binding activity, to pharmaceutical compositions containing them and to their medical use, particularly in the treatment of CNS conditions. Described herein are compounds which have the general formula: ##STR1## wherein R.sup.1 is selected from H, C.sub.1-6 alkyl and benzyl;R.sup.2 is selected from H and C.sub.1-6 alkyl;R.sup.3 is selected from H and C.sub.1-6 alkyl;R.sup.4 is selected from C.sub.1-6 alkyl and halo;R.sup.5 is selected from H and OH; andsalts, hydrates and solvates thereof.Also described is the use of these compounds as pharmaceuticals to treat indications where stimulation of subtypes of the serotonin receptor is implicated, such as migraine.

Abstract: The invention relates to methods for the treatment of central nervous system disorders, neurological disorders, gastrointestinal disorders, drug abuse, angina, migraine, hypertension and depression by administering a pharmaceutical composition comprising an effective amount of certain sigma receptor ligands to a patient in need of such treatment. The invention further relates to novel sigma receptor ligands having high binding to the sigma receptor and pharmaceutical compositions thereof.

Abstract: The invention relates to methods for the treatment of central nervous system disorders, gastrointestinal disorders, drug abuse, angina, migraine, hypertension and depression by administering a pharmaceutical composition comprising an effective amount of certain sigma receptor ligands to a patient in need of such treatment. The invention further relates to novel sigma receptor ligands having high binding to the sigma receptor and pharmaceutical compositions thereof. Unexpectedly, certain of the sigma receptor ligands of the present invention have selectivity for the sigma receptor over the DA, PCP and 5-HT.sub.1A receptors.

Abstract: This invention relates to compounds having serotonin receptor binding activity and to their medical use, particularly in the treatment of CNS conditions such as migraine. Described herein are compounds which have the general formula: ##STR1## wherein R.sup.1 is selected from a group of Formula i and ii: ##STR2## n is 1-3; R.sup.2 is selected from H and C.sub.1-6 alkyl;R.sup.3 is selected from H and C.sub.1-6 alkyl;R.sup.4 is selected from C.sub.1-6 alkyl, halo, phenyl, amino and nitro;R.sup.5 is selected from H, C.sub.1-6 alkyl and arylalkyl;R.sup.6 is selected from H or a alkylene group which is bonded to R.sup.4 to form the naphthalene ring skeleton; and salts, hydrates and solvates thereof.

Abstract: This invention relates to compounds having serotonin receptor binding activity, to pharmaceutical compositions containing them and to their medical use, particularly in the treatment of CNS conditions. Described herein are compounds which have the general formula: ##STR1## wherein R.sup.1 is selected from a group of Formula i and ii: ##STR2## n is 1-3; R.sup.2 is selected from H and C.sub.1-6 alkyl;R.sup.3 is selected from H and C.sub.1-6 alkyl;R.sup.4 is selected from C.sub.1-6 alkyl, halo, phenyl, amino and nitro;R.sup.5 is selected from H, C.sub.1-6 alkyl and arylalkyl;R.sup.6 is selected from H or a alkylene group which is bonded to R.sup.4 to form the naphthalene ring skeleton; and salts, hydrates and solvates thereof.Also described is the use of these compounds as pharmaceuticals to treat indications where stimulation of subtypes of the serotonin receptor is implicated, such as migraine.

Abstract: Methods of using pharmaceutical tetrahydroisoquinoline compounds for learning and/or memory enhancement, and for treatment of dementia, cocaine dependence, depression, eating disorders, anxiety, or attention deficit disorder with hyperactivity (ADHD).

Abstract: Described herein are tryptamine analogs that display high binding affinity and selectivity for the 5-HT1D.beta. receptor, of the formula: ##STR1## wherein R.sup.1 is a group selected from aryl-C.sub.1-7 alkyl; aryl-C.sub.2-7 alkoxy; aryl-C.sub.2-7 alkanoyl and aryl-C.sub.1-7 alkanoyloxy, wherein said alkyl, alkoxy, alkanoyl and alkanoyloxy groups are optionally substituted by a C.sub.1-4 alkyl substituent and wherein said aryl group is optionally substituted by one or more substituent selected from hydroxyl, halogen, mercapto, linear or branched C.sub.1-4 alkyl, linear or branched C.sub.1-4 alkoxy, linear or branched C.sub.1-4 alkylthio, thiol substituted C.sub.1-4 alkyl and nitro substituted C.sub.1-4 alkyl;R.sup.2 and R.sup.3 are selected independently from H and C.sub.1-4 alkyl; andR.sup.4 is selected from H, C.sub.1-4 alkyl, aryl and arylC.sub.1-4 alkyl.

Abstract: Described herein are tryptamine analogs that display high binding affinity and selectivity for the 5-HT1D.beta. receptor, of the formula: ##STR1## wherein R.sup.1 represents a chain selected from C.sub.8-11 alkyl, C.sub.7-10 alkoxy, C.sub.8-11 alkanoyl and C.sub.7-10 alkanoyloxy wherein said chain is optionally substituted by hydroxyl, C.sub.1-4 alkyl or C.sub.1-4 alkoxy and wherein one of the intervening carbons of said chain is optionally replaced with a heteroatom selected from oxygen, nitrogen and sulfur;R.sup.2 and R.sup.3 each independently represent H or C.sub.1-3 alkyl; andR.sup.4 represents H, C.sub.1-4 alkyl, aryl or arylC.sub.1-4 alkyl;The compounds are useful as reagents for receptor identification and in receptor-based drug screening programs, and can also be used therapeutically to treat conditions for which administration of a 5-HT1D ligand is indicated, for example in the treatment of migraine.